布地奈德、沙丁胺醇雾化吸入联合孟鲁司特钠治疗小儿哮喘的疗效观察

Observation on Efficacy of Budesonide and Albuterol for Aerosol Inhalation Combined with Montelukast in Treatment of Pediatric Asthma

目的:探讨布地奈德、沙丁胺醇雾化吸入联合孟鲁司特钠治疗小儿哮喘的疗效。方法:回顾性选取2017年1月至2018年1月大连市妇女儿童医疗中心收治的支气管哮喘患儿120例,根据治疗方法的不同分为对照组与观察组,每组60例。在常规基础的治疗下,对照组患儿采用雾化吸入沙丁胺醇治疗,观察组患儿采用雾化吸入布地奈德、沙丁胺醇联合孟鲁司特钠治疗。观察两组患儿的临床疗效、临床症状体征消退时间及临床症状评分。结果:观察组患儿的总有效率为95.00%(57/60),明显高于对照组的73.33%(44/60),差异有统计学意义(P<0.05);观察组患儿气促缓解、喘憋消失、咳嗽消失、肺部啰音消失及肺部哮鸣音消失时间明显短于对照组,差异均有统计学意义(P<0.05);治疗后,观察组患儿咳嗽评分、胸闷评分及呼吸困难评分明显低于治疗前及对照组治疗后,差异均有统计学意义(P<0.05);观察组、对照组患儿不良反应发生率分别为8.33%(5/60)、11.67%(7/60),差异无统计学意义(P>0.05)。结论:布地奈德、沙丁胺醇雾化吸入联合孟鲁司特钠治疗小儿哮喘的疗效显著,可缩短治疗时间,且安全性高。

OBJECTIVE： To probe into the efficacy of budesonide and albuterol for aerosol inhalation combined with montelukast in treatment of pediatric asthma. METHODS： 120 child patients with asthma admitted into Dalian Municipal Women and Children＇s Medical Center from Jan. 2017 to Jan. 2018 were retrospectively selected and divided into control group and observation group according to different therapies, with 60 cases in each group. Based on conventional therapy, the control group was treated with albuterol for aerosol inhalation, while the observation group was given budesonide and albuterol for aerosol inhalation combined with montelukast. The clinical efficacy, clinical symptom indication regression time and clinical symptom scores of two groups were observed. RESULTS： The total effective rate of observation group was 95.00%（57/60）, which was significantly higher than that of the control group（73.33%, 44/60）, with statistically significant difference（P0.05）; the shortness of breath relief, wheezing disappeared, cough disappeared, sputum disappeared and wheezing rale disappeared of observation group were significantly shorter than those of the control group, with statistically significant differences（P0.05）; after treatment, the cough score, chest distress score and dyspnea score of observation group were significantly lower than those of before treatment and the control group, with statistically significant difference（P0.05）; the incidences of adverse drug reactions of observation group and control group were respectively 8.33%（5/60） and 11.67%（7/60）, the difference has no statistical significance（P0.05）. CONCLUSIONS： The efficacy of budesonide and albuterol for aerosol inhalation combined with montelukast in treatment of pediatric asthma is remarkable, which can shorten the time of therapy, with high safety.